Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs. Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way. They expect significant manufacturing increases to occur, starting in the back half of the year. CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.” Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter. |
Chris Pratt spends Mother's Day with wife Katherine Schwarzenegger and motherCannes kicks off with Greta Gerwig's jury and a Palme d'Or for Meryl StreepSydney bishop stabbing: Unreasonable to hide video for all users on X, Judge saysKylie Jenner wows in curveDoomsday prepper reveals what it is really like to live offHedge fund operators go on trial after multibillionKris Jenner honors her children with touching Mother's Day postHorrifying moment gunmen open fire and massacre eight people at Mexican beer warehouseFormer Mormon lifts the lid on how the cultGOP attorneys general sue Biden administration and California over rules on gas